Tuesday, Sept. 1, 2020 : Issue #1059 DISASTERS AVERTED — Near Miss Case Studies
SGLT2 Inhibitors for Kidney Disease |
|
Letter from the Editor
 Melinda Rodriguez, PharmD Candidate 2021, Lake Erie College of Osteopathic Medicine, is attempting to help us understand the concept of Biosimilars. Her drug class of choice to unravel the process is insulin. In her feature this week she looks at the radical changes the FDA has to make to allow the almost, but not quite, duplication of the branded product.
As this trend continues, it will be interesting to see if lower insulin prices will become the norm, or will PBM’s keep these products off formularies so they can get their branded rebates?
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
